Information on the target
Vivo Capital is a prominent private equity firm established in 1996, with its headquarters located in Palo Alto, California. The firm has built a robust portfolio comprising 231 companies, which includes a diverse range of funding rounds and acquisitions. As of October 2026, Vivo Capital remains an active investor, having participated in 14 funding rounds and completed one acquisition in the past year. The firm primarily focuses on investments in the United States and China, spanning various sectors, including Life Sciences and High Tech.
One of Vivo Capital's latest investments was a significant seed round in Serán BioScience on October 5, 2026, which also attracted participation from notable co-investors such as Biospring Partners and Bain Capital Life Sciences. With a dedicated team of 59 professionals, including 12 partners, Vivo Capital is well-positioned to leverage its extensive network and expertise in the healthcare sector.
Industry overview in the target’s specific country
The Biotechnology & Medical Research (NEC) industry in the United States is a dynamic and rapidly evolving sector, characterized by significant advancements in technology and research. The U.S. is home to a vast number of biotechnology firms, research institutions, and universities that drive innovation in drug development, genetic research, and medical devices. This industry benefits from a robust regulatory framework that supports research and development, fostering an environment conducive to breakthroughs in healthcare.
In recent years, the U.S. biotechnology sector has witnessed substantial growth, driven by increased investment in research and development, as well as a surge in demand for personalized medicine and advanced therapies. The COVID-19 pandemic further accelerated the focus on biotechnology, highlighting the importance of rapid vaccine development and the role of biotech firms in addressing public health challenges. As a result, many companies in this space have seen their valuations soar, attracting both public and private investment.
The U.S. government has also played a pivotal role in supporting the biotechnology industry through various funding initiatives and grants aimed at fostering innovation. The National Institutes of Health (NIH) and the Food and Drug Administration (FDA) are key players in this ecosystem, providing essential resources and regulatory guidance to biotech firms. This collaborative environment has positioned the U.S. as a global leader in biotechnology and medical research.
Moreover, the increasing collaboration between biotech companies and academic institutions has led to a thriving ecosystem that encourages knowledge transfer and innovation. Partnerships between industry…